Company Description
LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products and therapies for neurological and cardiac conditions worldwide.
The company operates in two segments, Cardiopulmonary and Neuromodulation. The Cardiopulmonary segment provides cardiopulmonary products, including heart-lung machines, oxygenators, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related accessories.
The Neuromodulation segment offers VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve; and devices that deliver neuromodulation therapy for treating difficult-to-treat depression and drug-resistant epilepsy.
The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers.
The company sells its medical devices through a combination of direct sales representatives, agents, and independent distributors.
LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom.
| Country | United Kingdom |
| Founded | 1987 |
| IPO Date | Feb 10, 1993 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 2,900 |
| CEO | Vladimir Makatsaria |
Contact Details
Address: 20 Eastbourne Terrace London, W2 6LG United Kingdom | |
| Phone | 44 20 3325 0660 |
| Website | livanova.com |
Stock Details
| Ticker Symbol | LIVN |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001639691 |
| CUSIP Number | G5509L101 |
| ISIN Number | GB00BYMT0J19 |
| Employer ID | 98-1268150 |
| SIC Code | 3845 |
Key Executives
| Name | Position |
|---|---|
| Vladimir A. Makatsaria | Chief Executive Officer and Director |
| Alex Shvartsburg C.M.A. | Chief Financial Officer |
| Michael D. Hutchinson | Senior Vice President, Chief Legal Officer and Company Secretary |
| Lindsey Little | Senior Director of Investor Relations |
| Deanna Wilke | Vice President of Corporate Communications |
| Philip Kowalczyk | Chief Strategy and Corporate Development Officer |
| Natalia Kozmina | Chief Human Resources Officer |
| Paul R. Buckman | President of Advanced Circulatory Support and GM of Transcatheter Mitral Valve Replacement |
| Stephanie Bolton | President of Global Epilepsy |
| Ahmet Tezel Ph.D. | Chief Innovation Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 17, 2025 | 8-K | Current Report |
| Feb 25, 2025 | IRANNOTICE | Notice of disclosure filed pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 |
| Feb 25, 2025 | 10-K | Annual Report |
| Feb 25, 2025 | 8-K | Current Report |
| Feb 13, 2025 | SCHEDULE 13G/A | Filing |
| Dec 11, 2024 | 144 | Filing |
| Dec 10, 2024 | 144 | Filing |
| Nov 1, 2024 | 8-K | Current Report |
| Oct 31, 2024 | IRANNOTICE | Notice of disclosure filed pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 |
| Oct 31, 2024 | 10-Q | Quarterly Report |